The clinical course was as baffling as it was prolonged. Earlier biopsies had revealed pigmented fungal elements, including thick-walled budding spores, but cultures repeatedly failed to identify a culprit. Multiple rounds of intravenous and oral antifungal therapy produced only partial and temporary improvement. One clue proved especially telling: the infection waxed and waned with the seasons, worsening in winter and partially receding in summer. That pattern would later make biological sense, because laboratory testing showed that the fungus is psychrotolerant, growing best at 26 degrees Celsius, poorly above 30 degrees, and not at all at 37 or 40 degrees. In other words, the organism thrives at temperatures closer to a cool room than to human core body temperature, which may explain why the infection stayed confined to the cooler surfaces of the skin for more than three decades.

To crack the case, researchers at the Institute of Dermatology of the Chinese Academy of Medical Sciences in Nanjing and their collaborators turned to molecular tools. Because the isolate refused to produce conidia, the spore-like reproductive structures that mycologists normally use for identification, on any of six different culture media or under any lighting condition, the team sequenced four genetic barcodes: the internal transcribed spacer region, the large subunit ribosomal RNA gene, translation elongation factor 1-alpha, and RNA polymerase II’s second largest subunit. Sequence comparisons and phylogenetic analysis placed the clinical isolate firmly within the Brunneofusispora hyalina clade, matching the ex-type strain of a species described only in 2021. The isolate has been designated strain CAMS-CCPM-D 05816 and its sequences deposited in GenBank, giving future clinicians a reference point for recognizing similar infections.

The patient’s own genome held the other half of the explanation. Whole-exome sequencing revealed two heterozygous variants in the CARD9 gene, which encodes an adaptor protein central to antifungal immunity. One was a frameshift variant classified as pathogenic, the other a synonymous change of uncertain significance. CARD9 deficiency is a well-established inborn error of immunity that impairs interleukin-17-mediated responses, the arm of the immune system that guards skin and mucosa against fungi, and it predisposes carriers to invasive infections by both yeasts and melanized molds. Previous research has shown that CARD9 mutations are linked to subcutaneous phaeohyphomycosis and deficits in Th17 cell function, and a striking concentration of such infections has been documented in East Asia, where a founder mutation is prevalent and where environmental exposure to diverse dematiaceous fungi may add further risk.

Whole-genome sequencing of the fungus itself added a layer of technical depth to the story. The assembly, built from Illumina reads at roughly 125-fold coverage, spans about 44.5 megabases with a GC content of 48.76 percent, values consistent with other black yeasts and their relatives. Gene prediction yielded 13,777 genes, and functional annotation revealed substantial metabolic versatility, with secondary metabolite biosynthesis, carbohydrate transport, and amino acid metabolism among the most heavily represented functional categories. Most intriguingly, a search against the Pathogen-Host Interactions database identified 395 homologs of known virulence or pathogenicity proteins, but more than seventy percent of the top matches came from plant-pathogenic fungi such as Magnaporthe oryzae and Fusarium graminearum, with only a small share corresponding to human pathogens. The authors caution that sequence homology alone does not confirm virulence function, since many matches involve deeply conserved housekeeping proteins, but the pattern suggests B. hyalina lacks specialized weapons for attacking humans and instead exploits weaknesses in host defenses.

Determining which drugs could actually inhibit this unusual organism posed its own methodological challenge. Because the fungus would not sporulate and grew slowly, the standard CLSI M38 broth microdilution protocol, which depends on a standardized conidial inoculum, could not be applied directly. The team instead developed a modified agar dilution test using hyphal fragments and adapted a broth dilution method, testing six antifungal agents in triplicate with quality-control strains. The results were encouraging for the newer agents: voriconazole, posaconazole, and itraconazole all showed low minimum inhibitory concentrations, and terbinafine was the most potent of all at 0.25 to 0.5 micrograms per milliliter. Fluconazole, by contrast, required a concentration of 128 micrograms per milliliter to inhibit growth, marking the isolate as effectively resistant. Amphotericin B produced a notable discrepancy, with the agar method suggesting an MIC above 16 micrograms per milliliter while the broth method yielded 2, a gap of more than three twofold dilution steps that underscores how testing methodology can reshape interpretation for slow-growing molds.

To test whether the fungus’s modest virulence truly depends on a permissive host, the researchers built an infection model in mice. Wild-type C57BL/6 mice injected subcutaneously in the footpad developed a sharp inflammatory swelling in the first week, but the inflammation subsided rapidly, and by week eight the difference between infected and control paws had shrunk to just 0.04 millimeters, indicating resolution. CARD9 knockout mice told a different story: their paws remained chronically swollen between roughly 1.08 and 1.42 millimeters throughout eight weeks of observation, with no mortality but no spontaneous recovery either. This mirrors the human case in miniature, a persistent, localized, granulomatous infection that never turns lethal but never lets go, and it contrasts with more virulent dematiaceous fungi such as Fonsecaea pedrosoi, which can kill CARD9-deficient mice.

The treatment experiments were sobering. Starting three weeks after infection, knockout mice received oral voriconazole and terbinafine at doses converted from standard adult regimens using body-surface-area calculations. Within the first week of therapy, paw swelling fell more than fourfold relative to untreated knockout controls, and fungal burden in the infected tissue dropped by more than half. Yet after six weeks of combination therapy, residual swelling persisted, and histopathology with PAS and H&E staining still revealed granulomatous inflammation and viable fungal hyphae in the skin. The drug combination reduced the disease but could not eradicate the pathogen, a finding that echoes the patient’s own experience of relapse after a full year of posaconazole monotherapy. She is currently maintained on posaconazole plus terbinafine with good control, but the fungus was re-isolated once before, after she stopped the earlier treatment.

Taken together, the study reframes how a rarely seen environmental saprotroph becomes a clinical problem. The fungus carries a plant-associated genetic toolkit, tolerates only cool temperatures, and shows no obvious capacity for deep tissue invasion or systemic spread; what it needs is an opening, which in this case came in the form of a heterozygous CARD9 variant that blunted the IL-17-dependent defenses of the skin. The authors argue that where host immunity is the weak link, antifungal drugs alone may be insufficient, and they point to two complementary strategies worth exploring: immune restoration to rebuild the defective antifungal response, and local hyperthermia, which becomes conceptually attractive given that exposure to 40 degrees Celsius irreversibly killed the organism in culture, although they emphasize that such approaches remain untested hypotheses rather than clinical recommendations. For now, the case stands as both a taxonomy milestone and a cautionary one, expanding the roster of dematiaceous fungi capable of causing phaeohyphomycosis and reminding clinicians that in patients with recurrent or atypical dark skin lesions that resist conventional therapy, the answer may lie not only in the culture dish but also in the patient’s own DNA.

Subject of Research: Opportunistic cutaneous phaeohyphomycosis caused by the newly described environmental fungus Brunneofusispora hyalina in a patient with a heterozygous CARD9 variant

Article Title: Persistent cutaneous phaeohyphomycosis caused by Brunneofusispora hyalina in a patient with a heterozygous CARD9 variant: the opportunistic potential of a newly described environmental fungus

Article References: Mei, H., Li, D., Jing, D., Wang, X., Deng, S., Daly, P., Zheng, H., She, X., Fu, M., & Liu, W. (2026). Persistent cutaneous phaeohyphomycosis caused by Brunneofusispora hyalina in a patient with a heterozygous CARD9 variant: the opportunistic potential of a newly described environmental fungus. Frontiers in Fungal Biology, 7, Article 1938341. https://doi.org/10.3389/ffunb.2026.1938341

Image Credits: AI Generated

DOI: 10.3389/ffunb.2026.1938341

Keywords: Brunneofusispora hyalina, phaeohyphomycosis, CARD9, dematiaceous fungi, antifungal susceptibility, whole-genome sequencing, murine infection model, medical mycology, immunodeficiency, triazoles, terbinafine, Pleosporales

The disease itself begins deceptively small. Chromoblastomycosis is an implantation mycosis, meaning the fungi responsible enter the body through traumatic inoculation, typically when a thorn, splinter, or plant fragment carrying pigmented, soil-dwelling fungi pierces the skin of an agricultural worker. Over months and years, the infection progresses through verrucous, nodular, and plaque-like lesions that can spread along lymphatic pathways, and in advanced cases causes fibrosis, lymphedema, and disfiguring scarring. Although mortality is comparatively low, morbidity is considerable and durable: lesions can persist for decades, secondary bacterial infection is common, and squamous cell carcinoma can arise in long-standing scars. The condition predominantly affects rural populations in tropical and subtropical regions, particularly impoverished people who work barefoot or with exposed skin in contact with vegetation and soil.

Perhaps the most striking finding in the recent literature is how much the epidemiological picture has expanded. Historically associated with impoverished rural settings in Latin America, Africa, and Asia, chromoblastomycosis is now increasingly reported in both endemic and non-endemic areas, including high-income countries. Some of these cases reflect travel and migration, but others point to genuine local transmission in regions previously thought to be at low risk. This shifting landscape suggests that the true burden of disease is underrecognized. The authors emphasize a sobering metric gap: even basic measures of population impact, such as disability-adjusted life years, remain undefined for chromoblastomycosis, a deficiency recently highlighted by global health initiatives that have called for better quantification of fungal disease burden. Without such metrics, the disease struggles to compete for attention, funding, and drug development against conditions whose costs are more visible on public health dashboards.

On the biological side, however, the past two decades have been remarkably productive. Molecular taxonomy, built on DNA sequencing of fungal markers and whole genomes, has substantially reshaped our understanding of the etiological agents. The traditional picture cast the disease as caused by a handful of pigmented fungi, most prominently Fonsecaea pedrosoi and Cladophialophora carrionii. Sequencing studies have since revealed far greater biodiversity, with novel genera and species identified among clinical isolates, particularly from immunocompromised hosts. These discoveries matter clinically as well as academically, because different species can differ in virulence, geographic distribution, and response to antifungal therapy, and because fungi once lumped together under old names may behave differently in the human host. The recognition of new agents of disease in patients with weakened immunity has reshaped our understanding of host-pathogen interactions in this infection.

Diagnostics have advanced in parallel, at least in the laboratory. Polymerase chain reaction-based assays and genomic approaches now allow species-level identification that is far more precise than morphology, which has always been tricky with dematiaceous fungi that share overlapping microscopic features. Histopathology, culture, and the direct visualization of the pathognomonic muriform cells, the thick-walled, dark-brown, dividing fungal structures found in tissue, remain the backbone of diagnosis in practice. Molecular tools have improved species-level identification considerably, but the synthesis is blunt about their limitations: availability remains largely restricted to reference centers. In the endemic settings where most patients live, diagnosis continues to rely on low-cost conventional methods. The authors make a counterintuitive but important point here: precisely because those conventional methods are inexpensive, and despite imperfect sensitivity, they should be more widely incorporated into public health screening and active case-finding strategies rather than waiting for technology transfer that may never arrive.

Therapeutics present a similarly mixed picture. Extended-spectrum triazoles, such as itraconazole and the newer agents posaconazole and voriconazole, together with terbinafine, an allylamine antifungal that inhibits fungal squalene epoxidase, have shown the most consistent activity against the causative fungi. Treatment traditionally combines these systemic antifungals with physical approaches, including surgical excision for smaller lesions and cryotherapy with liquid nitrogen for accessible plaques, and combinations of drugs and techniques are often used for refractory disease. Yet even the best outcomes come slowly: therapy frequently spans months to years, relapse is common, and advanced lesions may never resolve fully. The evidence underpinning these choices is thin. Antifungal susceptibility testing lacks clear clinical correlation, meaning laboratory minimum inhibitory concentrations do not reliably predict whether an individual patient will respond to a given drug. Treatment decisions remain largely based on observational studies and expert experience, in the absence of randomized controlled trials.

Into this therapeutic landscape, the authors highlight emerging adjunctive immunomodulatory strategies, with imiquimod standing out as the most promising. Imiquimod is a topical immune response modifier that activates toll-like receptor 7, effectively recruiting the host’s own innate and adaptive immune machinery against the pathogen. This is an appealing logic for chromoblastomycosis, since the muriform cells that persist in tissue are notoriously resistant to direct antifungal killing, and host immunity appears central to controlling the infection. Used alongside systemic antifungals, imiquimod has shown encouraging results in case series, particularly for patients whose lesions respond poorly to drugs alone. Such approaches represent a conceptual shift: rather than simply escalating antifungal exposure, clinicians may be able to tilt the host-pathogen balance toward clearance. Still, the evidence base remains small, and the authors are careful to frame these strategies as emerging alternatives rather than established standards.

The deeper problem the synthesis identifies is structural. New technologies have not been incorporated into broader clinical and public health interventions. Molecular species identification improves taxonomies in reference laboratories in Europe and North America while a farmer in Madagascar or Brazil waits weeks for a culture result and then faces years of therapy with drugs that may be unaffordable or unavailable locally. Novel agents with better activity profiles exist on paper, but no pharmaceutical industry incentive drives the trials that would establish optimal regimens for a disease affecting dispersed, poor, rural populations. The absence of randomized controlled trials is not an accident of oversight but a predictable consequence of neglect: chromoblastomycosis lacks the defined burden metrics, the surveillance infrastructure, and the market forces that normally attract trial investment. The result is a field rich in descriptive biology and poor in implementation evidence.

The authors argue that closing this gap requires a deliberate rebalancing of priorities. Strengthening public health strategies means training primary care workers in endemic regions to recognize early lesions, since disease caught at the verrucous or nodular stage is far more treatable than disease caught after years of misdiagnosis as cutaneous leishmaniasis, tuberculosis, or carcinoma. Expanding access to simple and effective diagnostic tools means deploying the muriform-cell smear and culture more aggressively rather than reserving confirmation for molecular methods. Prioritizing implementation-focused research means studying how to deliver existing therapy to real patients, what drug combinations and durations work in programmatic settings, and what the true costs of disability actually are. International efforts to elevate fungal diseases within the neglected tropical disease agenda offer a policy opening, and the recent attention to undefined DALYs suggests momentum for better burden estimates.

Chromoblastomycosis, in the end, is a test case for the entire neglected tropical disease enterprise. The science has not stood still: new species have been named, genomes sequenced, susceptibility profiles catalogued, and immune-based adjuncts explored. But a century after the disease was first described, the measure of progress is not the number of novel taxa in the literature. It is whether the agricultural worker with a scaly foot lesion is diagnosed earlier, treated faster, and cured more completely. The synthesis by Santos, Smith, Vicente and their colleagues makes clear that on those measures, the gap between laboratory and clinic remains wide and persistent. Bridging it will require investment not in more discovery for its own sake, but in the unglamorous machinery of screening, surveillance, accessible diagnostics, and trials designed for the settings where the disease actually lives. Until then, chromoblastomycosis will remain a textbook example of how scientific knowledge can flourish while patients’ realities stand still.

Subject of Research: The gap between molecular research advances and clinical practice in chromoblastomycosis

Article Title: From molecular advances to limited clinical impact: The persistent gap in chromoblastomycosis

Article References: Santos, D. W. C. L., Smith, D. J., Vicente, V. A., Lustosa, B. P. R., & Azevedo, C. D. M. P. E. S. D. (2026). From molecular advances to limited clinical impact: The persistent gap in chromoblastomycosis. PLOS Neglected Tropical Diseases, 20(10), e0014801. https://doi.org/10.1371/journal.pntd.0014801

Image Credits: AI Generated

DOI: 10.1371/journal.pntd.0014801

Keywords: chromoblastomycosis, neglected tropical diseases, medical mycology, molecular diagnostics, antifungal therapy, terbinafine, triazoles, imiquimod, fungal taxonomy, public health, rural health, PLOS Neglected Tropical Diseases

The stakes in this line of research are extraordinarily high. Aspergillus fumigatus is an ubiquitous environmental mold whose spores drift through the air everyone breathes every day. For most people, inhaling these spores is harmless, because a healthy immune system clears them without difficulty. But for patients whose immune defenses are weakened, the same spores can germinate into a severe, rapidly progressing respiratory infection known as invasive aspergillosis. Vargas-Muñiz emphasized the severity of the problem, noting that even with treatment, mortality rates for the disease can range from 30 to 90 percent. Making matters worse, he added, environmentally acquired antifungal-resistant strains of Aspergillus are now beginning to infect patients, a trend that threatens to erode the effectiveness of the limited drug arsenal clinicians currently rely on.

The economic burden of the disease is also staggering. According to the study’s authors, invasive aspergillosis carries the highest per-patient cost of any invasive fungal disease, draining an estimated 1.3 billion dollars from the United States economy every year. Part of that cost stems from how difficult the infection is to diagnose. Busch pointed out that many people are simply unaware that these devastating fungal diseases exist, and that invasive fungal infections are notoriously hard to identify unless physicians already suspect what they are looking for. By the time a correct diagnosis is made, the infection may have advanced considerably, narrowing the window in which treatment can succeed.

The route to infection resembles that of other aerosolized pathogens. Just as hantavirus, influenza, and tuberculosis travel through inhaled droplets or particles, Aspergillus spores enter the body through the lungs. In immunocompetent individuals, innate immune cells engulf and destroy the inhaled spores before they can establish an infection. In patients with compromised immunity, however, the spores can germinate into invasive hyphae that penetrate lung tissue and spread through the bloodstream. Busch noted that this vulnerability is often compounded by common medications used to treat conditions such as psoriasis and rheumatoid arthritis, which can leave patients unknowingly immunocompromised and therefore susceptible to an infection they never saw coming.

Treatment options for invasive aspergillosis are strikingly narrow. The frontline therapy is the triazole class of antifungal drugs, which can kill the pathogen, but there is a catch: the triazoles used in medicine are chemically similar to agricultural fungicides sprayed on crops. That similarity has driven the emergence of resistant strains in the environment, meaning that some patients arrive already infected with fungus that the first-line drugs cannot touch. The second line of defense, the echinocandins, has a different limitation. These drugs do not kill Aspergillus fumigatus at all; they only stop its growth. Busch framed the problem bluntly, observing that while there are hundreds of antibacterial drugs available, there are only somewhere around ten antifungal drugs in total. Once a fungal strain is resistant, she asked, what else is there to treat the patient with?

To understand why echinocandins fail to deliver a killing blow, the research team turned its attention to the fungal cell wall, the structure that these drugs attack. Echinocandins work by inhibiting an enzyme complex that builds beta-glucan, a structural sugar that gives the fungal wall its strength. In many fungi, disrupting this synthesis is lethal, but Aspergillus fumigatus has evolved a remarkable capacity to remodel its cell wall in response to the assault, reinforcing weak points and maintaining enough integrity to survive. The fungus does not merely endure the drug; it adapts to it, switching into a defensive mode that keeps the cell intact until the pressure subsides.

Busch’s team hypothesized that specific regulatory proteins were orchestrating this survival response. To test the idea, they genetically modified the pathogen, stripping it of the proteins that govern cell wall architecture and remodeling. The strategy was essentially a process of elimination: by removing candidate regulators one by one and observing how the modified fungus responded to echinocandin treatment, the researchers could identify which proteins were integral to the pathogen’s defenses. Among the targets was a core septin gene known as aspB. Septins are cytoskeletal proteins that in fungi help organize the cell wall, coordinate growth, and manage stress responses, making them plausible architects of the drug-tolerance machinery the team wanted to dismantle.

The results were decisive. In both laboratory tests and animal studies, when the key cell wall regulatory machinery was removed, the echinocandin drug caspofungin was transformed from a growth-stalling agent into a fungicidal one, successfully killing the genetically modified pathogen. This outcome proved two things at once. First, it demonstrated the means by which these proteins normally prevent the drug from killing the fungus, revealing that the pathogen’s tolerance of echinocandins is an active, regulated process rather than a passive property of its biology. Second, it pinpointed which protein bears the greatest responsibility for that tolerance, giving drug developers a concrete molecular target to aim at.

With the weakness in their fungal opponent now identified, the researchers are strategizing more targeted attacks that would combine echinocandins with agents capable of disabling the protective machinery. The vision is a combination therapy in which one component knocks out the fungus’s remodeling defenses while the other delivers the lethal blow, converting a static drug into a killing one. Such an approach would not require inventing an entirely new antifungal compound, a notoriously difficult undertaking given the sparse pipeline of antifungal drug development. Instead, it would leverage an existing, already-approved drug class and sensitize the pathogen to it, potentially shortening the path from laboratory discovery to clinical benefit.

For Busch, the work is as much about awareness as it is about mechanism. She described the study as laying the groundwork for the future, and stressed that far too many people simply do not know that terrible fungal diseases like invasive aspergillosis exist. As immunocompromised patient populations grow and environmental resistance spreads from agricultural settings into clinics, the need for fungicidal strategies becomes ever more urgent. The Virginia Tech team’s findings do not yet constitute a new treatment, but they illuminate the molecular logic that has allowed one of medicine’s deadliest fungi to shrug off its best second-line therapy, and they chart a clear path toward defeating it. In the quiet war between human medicine and an airborne mold, the battle lines have finally begun to shift.

Subject of Research: Mechanisms of echinocandin tolerance and cell wall regulation in the fungal pathogen Aspergillus fumigatus

Article Title: A deadly fungus may not live to see the last of us

Article References: A deadly fungus may not live to see the last of us. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Aspergillus fumigatus, invasive aspergillosis, antifungal resistance, echinocandins, caspofungin, septins, aspB, fungal cell wall, Virginia Tech, immunocompromised patients, triazoles, Molecular Biology of the Cell